3.85 | 2.57%
CORE LABORATORIES NV's gross profit margin for the first quarter of its fiscal year 2013 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. CORE LABORATORIES NV has strong liquidity. Currently, the Quick Ratio is 1.56 which shows the ability to cover short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
During the same period, stockholders' equity ("net worth") has decreased by 13.54% from the same quarter last year. The key liquidity measurements indicate that the company is unlikely to face financial difficulties in the near future.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 260.93 | 234.19 |
| EBITDA ($mil) | 84.47 | 74.88 |
| EBIT ($mil) | 78.45 | 68.99 |
| Net Income ($mil) | 56.52 | 53.95 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 22.93 | 23.54 |
| Total Assets ($mil) | 655.44 | 610.68 |
| Total Debt ($mil) | 241.06 | 199.55 |
| Equity ($mil) | 182.01 | 210.53 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | 37.28 | 36.32 |
| EBITDA Margin | 32.37 | 31.97 |
| Operating Margin | 30.07 | 29.46 |
| Sales Turnover | 1.54 | 1.53 |
| Return on Assets | 33.35 | 31.49 |
| Return on Equity | 120.12 | 91.36 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 2.08 | 2.16 |
| Debt/Capital | 0.57 | 0.49 |
| Interest Expense | 2.27 | 2.19 |
| Interest Coverage | 34.57 | 31.5 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 46.01 | 47.55 |
| Div / share | 0.32 | 0.28 |
| EPS | 1.22 | 1.13 |
| Book value / share | 3.96 | 4.43 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 252286.0 | 340063.0 |
BUY. This stock's P/E ratio indicates a premium compared to an average of 21.41 for the Energy Equipment & Services industry and a significant premium compared to the S&P 500 average of 18.91. For additional comparison, its price-to-book ratio of 35.54 indicates a significant premium versus the S&P 500 average of 2.42 and a significant premium versus the industry average of 2.76. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, CORE LABORATORIES NV proves to trade at a premium to investment alternatives within the industry.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLB 30.30 | Peers 21.41 | CLB 25.70 | Peers 17.70 | |||||||||||||||||||||
|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations. CLB is trading at a significant premium to its peers. |
Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. CLB is trading at a significant premium to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| CLB 23.63 | Peers 16.07 | CLB 2.02 | Peers 2.01 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. CLB is trading at a significant premium to its peers. |
Average. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. CLB trades at a valuation on par to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| CLB 35.54 | Peers 2.76 | CLB 16.00 | Peers 20.98 | |||||||||||||||||||||
|
Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. CLB is trading at a significant premium to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, CLB is expected to trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| CLB 6.42 | Peers 2.10 | CLB 7.77 | Peers 18.09 | |||||||||||||||||||||
|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. CLB is trading at a significant premium to its industry. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. CLB significantly trails its peers on the basis of sales growth |
|||||||||||||||||||||||
